Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Diabetic Macular Edema (DME): early-phase trial registry

4 of 9 indexed Diabetic Macular Edema (DME) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Diabetic Macular Edema (DME): 9 US clinical trials tracked, 4 recruiting.

Diabetic Macular Edema (DME) is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is EyeBiotech, running 3 of these trials.

Enrollment posture brief

Registry condition diabetic-macular-edema-dme

OPEN 4 | RECR 44% | LATE 3 | EARLY 6 | RANK #1916 | SPON 3

Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Diabetic Macular Edema (this)44%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Diabetic Macular Edema (DME)

Diabetic Macular Edema (DME) lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Macular Edema (DME) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Macular Edema (DME) is recruiting below its size-band peers.

    4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Diabetic Macular Edema (DME) research.

    EyeBiotech accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Diabetic Macular Edema (DME) enrolment sits around 164 participants.

    Median target enrolment is 164 among the 9 trials that report a genuine target (sentinel values excluded). 3 of those (33.3%) plan for fewer than 100 participants.

  4. Diabetic Macular Edema (DME) research is mostly interventional.

    9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 32Phase 41

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 240 participants

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

EyePoint Pharmaceuticals

NCT07449923

RECRUITING Phase 3 240 participants

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

EyePoint Pharmaceuticals

NCT07449936

RECRUITING Phase 4 15 participants

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

Retina Consultants of Orange County

NCT06662994

RECRUITING Phase 1 9 participants

A Study of Avoralstat In Participants With Diabetic Macular Edema

BioCryst Pharmaceuticals

NCT07228559

ACTIVE NOT RECRUITING Phase 2 1,054 participants

A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

EyeBiotech

NCT06957080

ACTIVE NOT RECRUITING Phase 2 984 participants

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

EyeBiotech

NCT06571045

ACTIVE NOT RECRUITING Phase 2 150 participants

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Kyowa Kirin Co.

NCT06116916

ACTIVE NOT RECRUITING Phase 1 38 participants

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EyeBiotech

NCT06664502

COMPLETED Phase 1 164 participants

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Ollin Biosciences

NCT07484074

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Diabetic Macular Edema (DME) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ranibizumab Drug
2 trials
Aflibercept (2.0 mg) Drug
2 trials
EYP-1901 Drug
2 trials
EYE103 Drug
2 trials
OLN324 Drug
1 trials
EYE201 Drug
1 trials
KHK4951 Drug
1 trials
avoralstat Drug
1 trials

US sites by state

Facility locations filed on Diabetic Macular Edema (DME) trials. A trial with sites in several states counts in each.

California 9 trials
Arizona 6 trials
Texas 5 trials
Florida 5 trials
Maryland 4 trials
Connecticut 4 trials
Colorado 4 trials
North Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Macular Edema (DME) page

9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Diabetic Macular Edema (DME) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • EyeBiotech sponsors the most Diabetic Macular Edema (DME) trials on record, review their full trial history before evaluating a specific study. See EyeBiotech's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Macular Edema (DME) condition card totals 9 registered trials; most-linked intervention Ranibizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.